2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Leukemia
2
Depression
2
Tuberous Sclerosis
1
Tourette Syndrome
1
Tic Disorders
1
Preleukemia
1
Neurodevelopmental Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Hot Flashes
1
Hematologic Diseases
1
Glioblastoma
1
Fragile X Syndrome
1
DiGeorge Syndrome
1
Cytopenia
1
Breast Neoplasms
1
Bone Marrow Diseases
1
Autistic Disorder
1
Autism Spectrum Disorder
1
Attention Deficit Disorder with Hyperactivity
1
Anxiety Disorders
1
Anemia
1
22q11 Deletion Syndrome
1
Interventions
AP 1903 reagent
3
ON 01910
2
Biopsy
2
thymoglobulin
1
fludarabine phosphate
1
fludarabine
1
epacadostat
1
decitabine and cedazuridine drug combination
1
cedazuridine
1
angiotensin I (1-7)
1
Vitamin B 12
1
Therapeutics
1
Specimen Handling
1
Sertraline
1
Pluvicto
1
Peripheral Blood Stem Cell Transplantation
1
Metformin
1
Interleukin-8
1
Immunotherapy, Adoptive
1
IDO-1 inhibitor LY3381916
1
HuMax-IL8
1
Granulocyte Colony-Stimulating Factor
1
Genetic Counseling
1
Folic Acid
1
Filgrastim
1
Exercise
1
Emapalumab
1
Decitabine
1
DNA
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cytopenia
×
Sertraline
×
Clear all
NCT02452983
2022-06-02
SS1
Baylor College of Medicine
Phase 1
Terminated
14 enrolled